CorMedix Inc (CRMD)vsInsmed Inc (INSM)
CRMD
CorMedix Inc
$6.46
+0.62%
HEALTHCARE · Cap: $494.06M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 95% more annual revenue ($606.42M vs $311.71M). CRMD leads profitability with a 52.3% profit margin vs -2.1%. CRMD earns a higher WallStSmart Score of 70/100 (B-).
CRMD
Strong Buy70
out of 100
Grade: B-
INSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.4%
Fair Value
$13.87
Current Price
$6.46
$7.41 discount
Intrinsic value data unavailable for INSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 67 in profit
Keeps 52 of every $100 in revenue as profit
Strong operational efficiency at 53.9%
No standout strengths identified
Areas to Watch
3.1% revenue growth
Smaller company, higher risk/reward
Earnings declined 28.3%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 52.3% and operating margin at 53.9%.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CRMD
The primary concerns for CRMD are Revenue Growth, Market Cap, EPS Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CRMD profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
CRMD carries more volatility with a beta of 1.42 — expect wider price swings.
CRMD is growing revenue faster at 3.1% — sustainability is the question.
CRMD generates stronger free cash flow (94M), providing more financial flexibility.
Bottom Line
CRMD scores higher overall (70/100 vs 39/100), backed by strong 52.3% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?